Lymphadenopathy screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(One intermediate revision by one other user not shown) | |||
Line 2: | Line 2: | ||
{{Lymphadenopathy}} | {{Lymphadenopathy}} | ||
{{CMG}}; {{AE}} {{ADS}} | {{CMG}}; {{AE}} {{ADS}} [[Ogechukwu Hannah Nnabude, MD]] | ||
==Overview== | ==Overview== | ||
Line 11: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| |||
{{WH}} | |||
{{WS}} | |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date | [[Category:Up-To-Date]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 05:17, 9 December 2021
Lymphadenopathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphadenopathy screening On the Web |
American Roentgen Ray Society Images of Lymphadenopathy screening |
Risk calculators and risk factors for Lymphadenopathy screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2] Ogechukwu Hannah Nnabude, MD
Overview
There is insufficient evidence to recommend routine screening for lymphadenopathy
Screening
- There is insufficient evidence to recommend routine screening for lymphadenopathy